Web developed by Josh Bolinger website design

The Global Leader in Preclinical Ophthalmic Research


Proprietary MiDROPS™ technology is also available to formulate small lipohilic molecules for topical instillation (eyedrop).  This patented technology platform can deliver test agents to both the anterior and posterior segments of the eye.



EyeCRO provides numerous in-vivo research models to enable directed and meaningful preclinical drug discovery and development programs. EyeCRO also has extensive experience in various routes of administration and can customize studies depending on your needs. One of the main advantages in working with EyeCRO is our ability to be flexible.

EyeCRO and MPI Research Partner to Develop New Preclinical Models of Ophthalmic Disease

Oklahoma City, OK; Ann Arbor, MI; and Mattawan, MI (PRWEB) May 01, 2017 EyeCRO and MPI Research, … Read More

Inhibition of Stat3 by a Small Molecule Inhibitor Slows Vision Loss in a Rat Model of Diabetic Retinopathy

"Diabetic retinopathy is a leading cause of vision loss. Previous studies have shown signaling … Read More

Serum retinol-binding protein-induced endothelial inflammation is mediated through the activation of toll-like receptor 4

"Retinol-binding protein 4 (RBP4) is a novel adipokine (adipose-derived cytokine) that is clinically … Read More

More News

Monday, June 26th, 2017 at 10:51am
Bob Langer-backed biotech plots $86M IPO as FDA filings loom https://t.co/YVROAcl4aS via @BosBizJournal
Friday, June 23rd, 2017 at 3:26am
CRISPR could point to a cure for Huntington's disease, suggests new study - ScienceAlert https://t.co/lHeouzDhNL
Thursday, June 22nd, 2017 at 1:43pm
Untangling the complex puzzle of optic nerve regeneration https://t.co/xPk8EBS2YA via @medical_xpress
Thursday, June 15th, 2017 at 4:49am
Tisbury Pharmaceuticals Launches with a $32MMSeries A Financing to Develop First-in-class Therapeutics for Glaucoma https://t.co/rTOHjiW3Zt
Preclinical Ophthalmic Contract Research